Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury
Eckle, Tobias , Hughes, Kelly, Ehrentraut, Heidi , Brodsky, Kelley S. , Rosenberger, Peter , Ravid, Katya , Weng, Tingting, Xia, Yang , Blackburn, Michael R. , Choi, Doo‐Sup , Eltzschig, Holger K.

The FASEB Journal | April 19, 2013 | Volume: 27 | Issue: 8 | Pages: 3078-3089

10.1096/fj.13-228551 | PMID 23603835 Get It

The signaling molecule adenosine has been implicated in attenuating acute lung injury (ALI). Adenosine signaling is terminated by its uptake through equilibrative nucleoside transporters (ENTs). We hypothesized that ENT‐dependent adenosine uptake could be targeted to enhance adenosine‐mediated lung protection. To address this hypothesis, we exposed mice to high‐pressure mechanical ventilation to induce ALI. Initial studies demonstrated time‐dependent repression of ENT1 and ENT2 transcript and protein levels during ALI. To examine the contention that ENT repression represents an endogenous adaptive response, we performed functional studies with the ENT inhibitor dipyridamole. Dipyridamole treatment (1 mg/kg; EC 50 =10 μM) was associated with significant increases in ALI survival time (277 vs. 395 min; P <0.05). Subsequent studies in gene‐targeted mice for Ent1 or Ent2 revealed a selective phenotype in Ent2 ‐/‐ mice, including attenuated pulmonary edema and improved gas exchange during ALI in conjunction with elevated adenosine levels in the bronchoalveolar fluid. Furthermore, studies in genetic models for adenosine receptors implicated the A 2B adenosine receptor (Adora2b) in mediating ENT‐dependent lung protection. Notably, dipyridamole‐dependent attenuation of lung inflammation was abolished in mice with alveolar epithelial Adora2b gene deletion. Our newly identified crosstalk pathway between ENT2 and alveolar epithelial Adora2b in lung protection during ALI opens possibilities for combined therapies targeted to this protein set.—Eckle, T., Hughes, K., Ehrentraut, H., Brodsky, K. S., Rosenberger, P., Choi, D.‐S., Ravid, K., Weng, T., Xia, Y., Blackburn, M. R.Eltzschig, H. K., Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury. FASEB J. 27, 3078–3089 (2013). www.fasebj.org
Mediation of smoking-associated postoperative mortality by perioperative complications in veterans undergoing elective surgery: data from Veterans Affairs Surgical Quality Improvement Program (VASQIP)—a cohort study
Singh, Jasvinder A. , Hawn, Mary T. , Campagna, Elizabeth J., Henderson, William G., Richman, Joshua , Houston, Thomas K. , Singh, Jasvinder A

BMJ Open | April 19, 2013 | Volume: 3 | Issue: 4 | Pages: e002157

10.1136/bmjopen-2012-002157 | PMID 23604347 Get It

Objective To assess the mediation of smoking-associated postoperative mortality by postoperative complications. Design Observational cohort study. Setting Using data from the Veterans Affairs (VA) Surgical Quality Improvement Programme, a quality assurance programme for major surgical procedures in the VA healthcare system, we assessed the association of current smoking at the time of the surgery with 6-month and 1-year mortality. Primary and secondary outcome measures Using mediation analyses, we calculated the relative contribution of each smoking-associated complication to smoking-associated postoperative mortality, both unadjusted and adjusted for age, race/ethnicity, work relative value unit of the operation, surgeon specialty, American Society of Anesthesiologists class and year of surgery. Smoking-associated complications included surgical site infection (SSI), cardiovascular complications (myocardial infarction, cardiac arrest and/or stroke) and pulmonary complications (pneumonia, failure to wean and/or reintubation). Results There were 186 632 never smokers and 135 741 current smokers. The association of smoking and mortality was mediated by smoking-related complications with varying effects. In unadjusted analyses, the proportions of mediation of smoking to 6-month mortality explained by the complications were as follows: SSIs 22%, cardiovascular complications 12% and pulmonary complications 89%. In adjusted analyses, the per cents mediated by each complication were as follows: SSIs 2%, cardiovascular complications 4% and pulmonary complications 22%. In adjusted analyses for 1-year mortality, respective per cents mediated were 2%, 3% and 16%. Conclusions Pulmonary complications, followed by cardiovascular complications and SSIs were mediators of smoking-associated 6-month and 1-year mortality. Interventions targeting smoking cessation and prevention and early treatment of pulmonary complications has the likelihood of reducing postoperative mortality after elective surgery.
Pathways of Translation: Deep Brain Stimulation
Gionfriddo, Michael R. , Greenberg, Alexandra J. , Wahegaonkar, Abhijeet L., Lee, Kendall H.

Clinical and Translational Science | April 19, 2013 | Volume: 6 | Issue: 6 | Pages: 497-501

10.1111/cts.12055 | PMID 24330698 Get It

AbstractElectrical stimulation of the brain has a 2000 year history. Deep brain stimulation (DBS), one form of neurostimulation, is a functional neurosurgical approach in which a high‐frequency electrical current stimulates targeted brain structures for therapeutic benefit. It is an effective treatment for certain neuropathologic movement disorders and an emerging therapy for psychiatric conditions and epilepsy. Its translational journey did not follow the typical bench‐to‐bedside path, but rather reversed the process. The shift from ancient and medieval folkloric remedy to accepted medical practice began with independent discoveries about electricity during the 19th century and was fostered by technological advances of the 20th. In this paper, we review that journey and discuss how the quest to expand its applications and improve outcomes is taking DBS from the bedside back to the bench.
Statistical Evaluation of the Use of Concurrent Controls in Treatment Screening Studies
Carter, Rickey E. , Shi, Qian , Carter, Rickey E , Shi, Qian

Clinical and Translational Science | April 19, 2013 | Volume: 6 | Issue: 4 | Pages: 323-330

10.1111/cts.12042 | PMID 23919371 Get It

AbstractA well‐designed pilot study can advance science by providing essential preliminary data to support or motivate further research, refine study logistics, and demonstrate proof of concept. Often, the outcomes of such studies can be quantified by a success/failure dichotomy. For example, a novel compound may show activation of a neural pathway, or it may not. When an intervention's efficacy is quantified using a dichotomous outcome, probability mass functions can be enumerated to determine the probability that the observed result from a pilot study supports further evaluation of the intervention since there is only a finite, and often small, number of sample configurations possible. The purpose of this research was to determine the probability of an “efficacy signal” for pilot studies using one‐ and two‐sample pilot study designs. Efficacy signal was defined as the probability of observing a more favorable response proportion relative to a historical control (one‐sample setting) or to a concurrent control (two‐sample setting). An enumeration study (exact simulation) was conducted to calculate the efficacy signal probability. One‐sample study designs yielded higher probability of determining an efficacy signal than the two‐sample setting; however, sampling variation must be accounted for. A 68% score confidence interval is recommended for this purpose.
Construction of a US Fibromyalgia Registry Using the Fibromyalgia Research Survey Criteria
Whipple, Mary O. , McAllister, Samantha J., Oh, Terry H., Luedtke, Connie A. , Vincent, Ann, Toussaint, Loren , Whipple, Mary

Clinical and Translational Science | April 19, 2013 | Volume: 6 | Issue: 5 | Pages: 398-399

10.1111/cts.12056 | PMID 24127929 Get It

AbstractUtilizing billing records, we identified patients seen at Mayo Clinic with a diagnosis or history of fibromyalgia who were then contacted for enrollment in a fibromyalgia research registry. Fibromyalgia was confirmed through medical record review. Eligible patients were mailed an invitation that included a demographic questionnaire and the Fibromyalgia Research Survey. The Fibromyalgia Research Survey yields a widespread pain score (scale range 0–19) and a symptom severity score (scale range 0–12). A total of 4,034 patients returned the completed survey; 92.8% were female, their mean age was 57.4 (±13.4), and 83.7% were from the Midwest region of the United States. The mean widespread pain score for all participants was 11.3 (±4.5) and the mean symptom severity score was 8.2 (±2.4), indicating moderate‐to‐severe fibromyalgia symptoms, which is not unusual for patients presenting to a tertiary care center. Using a systematic process, we describe the creation of a fibromyalgia registry for future research.
FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein–Barr virus status
Ghesquières, Hervé , Link, Brian K. , Maurer, Matthew J. , Cunningham, Julie M. , Novak, Anne J. , Larrabee, Beth R. , Allmer, Cristine, Ansell, Stephen M. , Cerhan, James R. , Doǧan, Ahmet , Slager, Susan L. , Habermann, Thomas M. , Maurer, Matthew , Cerhan, James R , Link, Brian K

Leukemia & Lymphoma | April 19, 2013 | Volume: 54 | Issue: 11 | Pages: 2571-2573

10.3109/10428194.2013.796048 | PMID 23597143 Get It

Rescue Treatment of Thromboembolic Complications During Endovascular Treatment of Cerebral Aneurysms
Brinjikji, Waleed , Kallmes, David F. , Cloft, Harry J. , McDonald, Jennifer S.

Stroke | April 19, 2013 | Volume: 44 | Issue: 5 | Pages: 1343-1347

10.1161/strokeaha.111.000628 | PMID 23598522 Get It

Background and Purpose— Acute intraprocedural thrombus formation complicating endovascular cerebral aneurysm treatment is often treated with intra-arterial or intravenous administration of thrombolytic agents or glycoprotein IIb/IIIa (GpIIb/IIIa) inhibitors. We sought to evaluate the morbidity and mortality associated with such treatments using a large multihospital database. Methods— Using the Premier Perspective Database, we examined outcomes for patients receiving endovascular coiling for ruptured and unruptured aneurysms requiring rescue therapy, defined as treatment with GpIIb/IIIa inhibitors and fibrinolytic therapy. We compared discharge status, length of stay, and complication rates across 3 groups: (1) patients receiving GpIIb/IIIa inhibitors only, (2) patients receiving fibrinolytic therapy only, and (3) patients receiving both GpIIb/IIIa inhibitors and fibrinolytics. Student t test was used to compare continuous variables, and Fisher exact test was used to compare categorical variables. Results— Seven-percent (254/3627) of patients treated for unruptured aneurysms received rescue therapy. When compared with patients receiving GpIIb/IIIa inhibitors alone, patients receiving only fibrinolytics had significantly higher rates of discharge to institutions other than home (37.5% [9/24] versus 7.4% [15/201]; P <0.0001). Eight-percent of patients (338/4204) treated for ruptured aneurysms received rescue therapy. When compared with patients receiving GpIIb/IIIa inhibitors alone, patients receiving only fibrinolytics had significantly higher rates of mortality (26.0% [18/69] versus 14.5% [35/241]; P =0.02) and discharge to institutions other than home (59.4% [41/69] versus 36.5% [88/241]; P <0.0001). Conclusions— Pharmacological rescue therapy occurred in 7% to 8% of endovascular coiling patients with unruptured and ruptured intracranial aneurysms. Rescue therapy with thrombolytic agents resulted in significantly more morbidity and mortality than rescue therapy with GpIIb/IIIa inhibitors.
New research article preparation guidelines
Kurth, Tobias , Dodick, David W. , Kurth, Tobias

Cephalalgia | April 18, 2013 | Volume: 33 | Issue: 12 | Pages: 995-997

10.1177/0333102413483373 Get It

Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment
Gertz, Morie A.

American Journal of Hematology | April 18, 2013 | Volume: 88 | Issue: 5 | Pages: 416-425

10.1002/ajh.23400 | PMID 23605846 Get It

Disease OverviewImmunoglobulin (Ig) light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of Ig light chain are deposited in tissues. Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic failure, peripheral/autonomic neuropathy, and atypical multiple myeloma.DiagnosisTissue biopsy stained with Congo red demonstrating amyloid deposits with apple‐green birefringence is required for diagnosis. Invasive organ biopsy is not required because amyloid deposits can be found in bone marrow biopsy or subcutaneous fat aspirate in 85% of patients. Verification that amyloid is of immunoglobulin origin is mandatory.PrognosisN‐terminal pro–brain natriuretic peptide (NT‐proBNP), serum troponin T, and immunoglobulin free light chain values are used to classify patients into four groups of similar size; median survivals are 94.1, 40.3, 14.0, and 5.8 months.TherapyAll patients with a visceral amyloid syndrome require therapy to prevent deposition of amyloid in other viscera and prevent progressive organ failure of involved sites. Stem cell transplant (SCT) is preferred, but only 20% of patients are eligible. Requirements for safe SCT include NT‐proBNP <5,000 ng/mL, troponin T < 0.06 ng/mL, age <70 years, <3 organs involved, and serum creatinine ≤1.7 mg/dL. Nontransplant candidates can be offered melphalan‐dexamethasone. Pomalidomide appears to have activity, as do other combinations of chemotherapy with agents such as cyclophosphamide‐thalidomide (or lenalidomide or bortezomib)‐dexamethasone, bortezomib‐dexamethasone, and melphalan‐prednisone‐lenalidomide.Future ChallengesLate diagnosis remains a major obstacle to initiating effective therapy when organ dysfunction is still recoverable. Recognizing the presenting syndromes is necessary for improving survival. Am. J. Hematol. 88:417–425, 2013. © 2013 Wiley Periodicals, Inc.
Beyond phylotyping: understanding the impact of gut microbiota on host biology
Reigstad, Christopher S., Kashyap, Purna

Neurogastroenterology & Motility | April 18, 2013 | Volume: 25 | Issue: 5 | Pages: 358-372

10.1111/nmo.12134 | PMID 23594242 Get It

AbstractBackgroundMicrobial constituents of the gut microbiome interact with each other and the host to alter the luminal environment and impact development, motility, and homeostasis of the gut. Powerful methods are becoming available to investigate connections between the gut microbiome and human health. While high‐throughput sequencing of 16S rRNA genes can be used to identify and enumerate microbes in the gut, advances in several techniques (e.g., metagenomics, metatranscriptomics, metabolomics, and metaproteomics) are providing a clearer view as to the specific activities of the microbiota in the context of functional host–microbe interactions. Testing emergent hypotheses regarding microbial effects on host biology, which arise from analyses of ‘Big Data’ generated from massive parallel high‐throughput sequencing technology and spectroscopic techniques, to guide translational research is an important goal for the future. Insights regarding the fundamental operating principles of the gut microbiota should lay the foundation for rational manipulation of the microbiota to promote human health.PurposeIn this review, we provide an overview of current research on the gut microbiome emphasizing current state‐of‐the‐art technologies, approaches, and directions for improvement of our understanding of the impact of the gut microbiota with specific focus on gastrointestinal motility disorders.